Infectious Diseases Clinic, University clinical center of Republika Srpska, Banja Luka, Bosnia and Herzegovina
Klinički centar Srbije, Belgrade, Serbia
Faculty of Agriculture, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
Infectious Diseases Clinic, University clinical center of Republika Srpska, Banja Luka, Bosnia and Herzegovina
Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
Faculty of Medicine , University of Banja Luka, Banja Luka, Bosnia and Herzegovina
Introduction. Lyme borreliosis is a multisystem infectious disease caused by Borrelia burgdorferi sensu lato complex. It is transmitted by Ixodes ticks. Apart from erythema migrans, other manifestations require laboratory confirmation. The aim of our study was to analyze the results of Two-Tiered Testing in patients with possible Lyme neuroborreliosis (LNB).
Method. We conducted a prospective diagnostic study at the University Clinical Centre of Republic of Srpska from October 2017 to October 2021. The study included 51 patients exam ined and treated under suspicion of Lyme neuroborreliosis (LNB). We used Two-Tiered Testing through ELISA anti-Borrelia IgM/IgG and confirmatory Immunoblot anti-Borrelia test IgM/ IgG.
Results. ELISA anti-Borrelia IgM in serum was positive in 25.5% patients and IgG in 76.47%, while in cerebrospinal fluid (CSF) IgM was positive in 13.7% patients and IgG in 39.2%. Immuno blot test of anti-Borrelia IgM in serum was at the borderline in 7.84% patients, positive in 6.17% and no data for 35.29%, while IgG was positive in 54.9% of patients and no data for 37.25%. A strong correlation between results of ELISA anti-Borrelia IgM in serum and CSF was observed (ρ=0.802, p<0.001) and also between ELISA anti-Borrelia IgG and Immunoblot IgG in serum (ρ=0.787, p<0.001).
Conclusion. Two-Tiered Testing is very important in patients with possible LNB. False positive and false negative results are possible and test should be interpreted with caution and in correlation with the clinical manifestation and other avail able tests. More work needs to be done to develop new reli able diagnostic test for LNB, such as detection of CXCL13 in CSF, titrate the interleukin-6 (IL-6) in addition to the CXCL13 chemokine.
Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. 
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.